CNS Pharmaceuticals Inc Total Liabilities
CNS Pharmaceuticals Inc total liabilities. Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) has total liabilities worth $3.74 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CNSP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of CNS Pharmaceuticals Inc (2017–2025)
Total liabilities of CNS Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how CNS Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
CNS Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of CNS Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zwahlen et Mayr SA
SW:ZWM
|
Switzerland | CHF20.55 Million |
|
SolTech Energy Sweden AB
ST:SOLT
|
Sweden | Skr1.35 Billion |
|
Ignite Ltd
AU:IGN
|
Australia | AU$4.89 Million |
|
Huadi International Group Co Ltd
NASDAQ:HUDI
|
USA | $43.26 Million |
|
IMPIANTI S.P.A.
F:F67
|
Germany | €4.38 Million |
|
Ictsi Jasa Prima Tbk
JK:KARW
|
Indonesia | Rp44.68 Million |
|
Tri-Mode System M Bhd
KLSE:0199
|
Malaysia | RM78.39 Million |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
India | Rs206.50 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down CNS Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of CNS Pharmaceuticals Inc.
Liquidity & Leverage Metrics
CNS Pharmaceuticals Inc Total Liabilities Ratios Explained
CNS Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CNS Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CNS Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of CNS Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.10 Million | +62.46% |
| 2024-12-31 | $2.52 Million | -58.84% |
| 2023-12-31 | $6.13 Million | +24.65% |
| 2022-12-31 | $4.92 Million | +130.40% |
| 2021-12-31 | $2.14 Million | +12.08% |
| 2020-12-31 | $1.91 Million | +512.68% |
| 2019-12-31 | $311.00K | -74.77% |
| 2018-12-31 | $1.23 Million | +458.44% |
| 2017-12-31 | $220.73K | -- |
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more